ArticleFrontiers in neurology2021
Real-World Healthcare Resource Utilization and Cost Burden Assessment for Adults With Generalized Myasthenia Gravis in the United States.
Article in Frontiers in neurology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 2 syntheses or guidelines pooled it, 32 citations in OpenAlex.
- Health economic evaluations of myasthenia gravis: a systematic review.Croatian medical journal · 2026Pooled it
- Dyslipidemia in Myasthenia Gravis: A Systematic Review and Meta-Analysis.Medicina (Kaunas, Lithuania) · 2025Pooled it
- Real-world Treatment Patterns Among Patients with Generalized Myasthenia Gravis in the United States.Neurology and therapy · 2026Article
- Complications and Occurrence of Exacerbations in Patients with Myasthenia Gravis Treated with Oral Corticosteroids.Drugs - real world outcomes · 2026Article
- Myasthenia Gravis (MG) Resource Utilization, Epidemiology, Survival, and Treatment Patterns (MG-REST): Estimating the Clinical and Economic Burden in Ontario, Canada.European journal of neurology · 2026Article
- Incremental health care resource utilization, costs, and predictors of high costs in generalized myasthenia gravis.Journal of managed care & specialty pharmacy · 2026Article
- Article
- Health care costs and resource utilization among patients with myasthenia gravis in the United States.Journal of managed care & specialty pharmacy · 2025Article
- Racial disparities in acute care utilization among individuals with myasthenia gravis.Frontiers in public health · 2025Article
- Persistent symptoms, exacerbations and drug side effects despite treatment in myasthenia gravis.European journal of neurology · 2025Article
- Treatment patterns and impact of glucocorticoids on health outcomes in generalized myasthenia gravis: a retrospective observational study based on the Medical Data Vision database in Japan.Frontiers in neurology · 2025Article
- US Clinical Practice Experience with Eculizumab in Myasthenia Gravis: Acute Clinical Events and Healthcare Resource Utilization.Drugs - real world outcomes · 2024Article
- Risk-Benefit Analysis of Novel Treatments for Patients with Generalized Myasthenia Gravis.Advances in therapy · 2024Article
- Predictors of High Healthcare Cost Among Patients with Generalized Myasthenia Gravis: A Combined Machine Learning and Regression Approach from a US Payer Perspective.Applied health economics and health policy · 2024Article
- Article
- Patient perceptions of disease burden and treatment of myasthenia gravis based on sentiment analysis of digital conversations.Scientific reports · 2024Article
- A retrospective observational study on characteristics, treatment patterns, and healthcare resource use of patients with myasthenia gravis in England.Therapeutic advances in neurological disorders · 2024Article
- Long-Term Healthcare Resource Utilization and Costs among Patients with Myasthenia Gravis: A Swedish Nationwide Population-Based Study.Neuroepidemiology · 2024Observational
- The safety and efficacy profile of eculizumab in myasthenic crisis: a prospective small case series.Therapeutic advances in neurological disorders · 2024Article
- Independent risk factors for in-hospital outcome of myasthenic crisis: a prospective cohort study.Therapeutic advances in neurological disorders · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionLimited evidence exists for healthcare resource utilization (HCRU) and costs associated with generalized myasthenia gravis (gMG), a rare autoimmune disorder, for adults in the United States.
methodsAdults with ≥1 diagnostic claim for MG between 2014 and 2019 were identified using Symphony Health's Integrated Dataverse®. Using a novel algorithm, HCRU and costs over 12 months following index dates were evaluated for patients with gMG including those with exacerbation events. For patients who experienced crisis events, HCRU and costs were analyzed during the 36 months preceding, during, and 12 months following the events.
resultsMean HCRU and costs were higher for newly diagnosed patients compared with previously diagnosed patients (hospitalizations: 0.46 vs. 0.34; all-cause costs: $26,419.20 vs. $24,941.47; direct costs for gMG treatments: $9,890.37 vs. $9,186.47) and further increased for patients with exacerbation events (hospitalizations: 0.72; all-cause costs: $43,734.15; direct costs for gMG treatments: $21,550.02). For patients who experienced crisis events, HCRU and costs markedly increased during the 12 months immediately before the crisis event (hospitalizations: 1.35; all-cause costs: $49,236.68) compared with the 2 preceding years and increased further during the 12 months following the crisis index date (hospitalizations: 2.78; all-cause costs: $173,956.99). Cost increases were, in large part, attributed to treatments received. DISCUSSION: New diagnosis, exacerbation, and crisis events were drivers of HCRU and cost for patients with gMG. Particularly, high costs of gMG-specific medications associated with intervention for exacerbation and crisis events contributed to increased all-cause costs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.